Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect?

Overview

Journal ORL J Otorhinolaryngol Relat Spec

Specialty Otorhinolaryngology

Date 2024 Jun 11

PMID 38861957

Authors

Janine Gellrich

Linda Czaplewski

Antje Hahner

Thomas Hummel

Affiliations

Soon will be listed here.

Abstract

Introduction: The prevalence of post-viral olfactory dysfunction has increased significantly during the COVID-19 pandemic, posing a major challenge for patients and practitioners. While olfactory training (OT) is a common approach to therapy, there has been increasing interest in supplementing therapy with a combination of palmitoylethanolamide (PEA) and luteolin (LUT), which are known for their anti-inflammatory properties. In this study, their efficacy in the treatment of patients with olfactory loss following upper respiratory tract infections, mainly COVID-19, was investigated in an outpatient clinic.

Methods: Fifty patients with persistent olfactory dysfunction were randomized to two groups: one receiving OT and PEA-LUT, the other OT alone. Olfactory function was evaluated before and after treatment.

Results: The study group showed significant improvements in odor discrimination and overall olfactory function (TDI score) after treatment with PEA-LUT and OT, while the control group did not. However, when clinically meaningful improvements were considered, there was no significant difference between the groups.

Conclusion: The present study suggests that while PEA-LUT may have the potential to improve olfactory function in post-viral dysfunction, the additional benefit over OT alone may be limited. These results contrast with some previous studies.

References

De Luca P, Camaioni A, Marra P, Salzano G, Carriere G, Ricciardi L . Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. 2022; 11(16). PMC: 9406356. DOI: 10.3390/cells11162552. View

Oliviero A, de Castro F, Coperchini F, Chiovato L, Rotondi M . COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?. Neuroscientist. 2020; 27(3):214-221. DOI: 10.1177/1073858420939033. View

Khan A, Kallogjeri D, Piccirillo J . Growing Public Health Concern of COVID-19 Chronic Olfactory Dysfunction. JAMA Otolaryngol Head Neck Surg. 2021; 148(1):81-82. PMC: 8603223. DOI: 10.1001/jamaoto.2021.3379. View

Gudziol V, Lotsch J, Hahner A, Zahnert T, Hummel T . Clinical significance of results from olfactory testing. Laryngoscope. 2006; 116(10):1858-63. DOI: 10.1097/01.mlg.0000234915.51189.cb. View

DAscanio L, Vitelli F, Cingolani C, Maranzano M, Brenner M, Di Stadio A . Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results. Eur Rev Med Pharmacol Sci. 2021; 25(11):4156-4162. DOI: 10.26355/eurrev_202106_26059. View

Butowt R, Bilinska K, von Bartheld C . Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019. J Infect Dis. 2022; 226(8):1304-1308. PMC: 9129133. DOI: 10.1093/infdis/jiac113. View

Hummel T, Sekinger B, Wolf S, Pauli E, Kobal G . 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997; 22(1):39-52. DOI: 10.1093/chemse/22.1.39. View

Muccioli G, Stella N . Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology. 2007; 54(1):16-22. PMC: 2254322. DOI: 10.1016/j.neuropharm.2007.05.015. View

Skaper S, Facci L, Giusti P . Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013; 48(2):340-52. DOI: 10.1007/s12035-013-8487-6. View

10.

Stadio A, Cantone E, De Luca P, Di Nola C, Massimilla E, Motta G . Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial. Biomedicines. 2023; 11(4). PMC: 10135838. DOI: 10.3390/biomedicines11041109. View

11.

Guida F, Luongo L, Boccella S, Giordano M, Romano R, Bellini G . Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017; 7(1):375. PMC: 5428303. DOI: 10.1038/s41598-017-00342-1. View

12.

Aziz N, Kim M, Cho J . Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018; 225:342-358. DOI: 10.1016/j.jep.2018.05.019. View

13.

Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Huttenbrink K . Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009; 119(3):496-9. DOI: 10.1002/lary.20101. View

14.

Stadio A, DAscanio L, Vaira L, Cantone E, De Luca P, Cingolani C . Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial. Curr Neuropharmacol. 2022; 20(10):2001-2012. PMC: 9886808. DOI: 10.2174/1570159X20666220420113513. View

15.

Oleszkiewicz A, Schriever V, Croy I, Hahner A, Hummel T . Updated Sniffin' Sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol. 2018; 276(3):719-728. PMC: 6411676. DOI: 10.1007/s00405-018-5248-1. View

16.

Whitcroft K, Hummel T . Olfactory Dysfunction in COVID-19: Diagnosis and Management. JAMA. 2020; 323(24):2512-2514. DOI: 10.1001/jama.2020.8391. View

17.

Damm M, Pikart L, Reimann H, Burkert S, Goktas O, Haxel B . Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2013; 124(4):826-31. DOI: 10.1002/lary.24340. View

18.

Nabavi S, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wozniak K . Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Res Bull. 2015; 119(Pt A):1-11. DOI: 10.1016/j.brainresbull.2015.09.002. View